Target cell-restricted apoptosis induction by 528scFv-TRAIL fusion protein specific for human EGFR and expressed in Escherichia coli

International Journal of Oncology

Volumn 36, Issue 5, 2010, Pages 1229-1234

  Badran, Adel ^a   Asano, Ryutaro ^a   Nakayama, Makoto ^a   Watanabe, Yasuhiro ^b   Nakanishi, Takeshi ^a   Umetsu, Mitsuo ^a   Hayashi, Hiroki ^b   Katayose, Yu ^b   Unno, Michiaki ^b   Kumagai, Izumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; E. coli; EGFR; Fusion protein; scFv; TRAIL

Indexed keywords

528SCFV TRAIL HYBRID PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CELL INCLUSION; CELL PROLIFERATION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; FLOW CYTOMETRY; GEL FILTRATION; GENE CONSTRUCT; GENETIC CODE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; SOLUBILITY; TARGET CELL;

ANTIBODIES; APOPTOSIS; CELL LINE, TUMOR; CHROMATOGRAPHY, GEL; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77950450379     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000606     Document Type: Article

References (39)

1. Weisser NE and Hall JC: Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 27: 502-520, 2009.
2. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
3. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C and Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
5. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818, 1997.
6. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997.
7. Wu GS, Burns TF, McDonald ER III, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G and el-Deiry WS: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143, 1997.
8. Lahm A, Paradisi A, Green DR and Melino G: Death fold domain interaction in apoptosis. Cell Death Differ 10: 10-12, 2003.
9. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY and Screaton GR: Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 6: 1048-1053, 1999.
10. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588, 1995.
11. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH and Walczak H: FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609, 2000.
12. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12: 611-620, 2000.
13. Stennicke HR, Jurgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, Zhou Q, Ellerby HM, Ellerby LM, Bredesen D, Green DR, Reed JC, Froelich CJ and Salvesen GS: Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 273: 27084-27090, 1998.
14. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS and Vogelstein B: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89: 2965-2969, 1992.
15. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P and Zeillinger R: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17: 613-619, 1997.
16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
17. Nonomura A, Ohta G, Nakanuma Y, Izumi R, Mizukami Y, Matsubara F, Hayashi M, Watanabe K and Takayanagi N: Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF), and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 8: 157-166, 1988.
18. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth-factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
19. De Jong JS, van Diest PJ, van der Valk P and Baak JP: Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J Pathol 184: 53-57, 1998.
20. Gibson S, Tu S, Oyer R, Anderson SM and Johnson GL: Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for activation. J Biol Chem 274: 17612-17618, 1999.
21. Giordano A, Rustum YM and Wenner CE: Cell cycle: molecular targets for diagnosis and therapy-tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem 70: 1-7, 1998.
22. Kerbel RS, Viloria-Petit A, Okada F and Rak J: Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4: 286-295, 1998.
23. Turner T, Chen P, Goodly LJ and Wells A: EGF-receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 14: 409-418, 1996.
24. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T and Rijksen G: Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast-cancer cells and NIH3T3 fibroblasts. FEBS Lett 425: 145-150, 1998.
25. Wells A: Tumor invasion: role of growth-factor-induced cell motility. Adv Cancer Res 78: 31-101, 2000.
26. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH and Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337-1341, 1983.
27. Hayashi H, Asano R, Tsumoto K, Katayose Y, Suzuki M, Unno M, Kodama H, Takemura S, Yoshida H, Makabe K, Imai K, Matsuno S, Kumagai I and Kudo T: A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother 53: 497-509, 2004.
28. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR and Pluckthun A: Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 201: 35-55, 1997.
29. Hymowitz S, O'Connell M, Ultsch M, Hurst A, Totpal K, Ashkenazi A, De Vos A and Kelly R: A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39: 633-640, 2000.
30. Tsumoto K, Shinoki K, Kondo H, Uchikawa M, Juji T and Kumagai I: Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent: application to a human single-chain Fv fragment. J Immunol Methods 219: 119-129, 1998.
31. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T and Kumagai I: Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 282: 27659-27665, 2007.
32. Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M, Sone Y, Asano R and Kumagai I: Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem 283: 1156-1166, 2008.
33. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo M and Chan F: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis6. Proc Natl Acad Sci USA 50: 18099-18104, 2005.
34. Shen YL, Xia XX, Zhang Y, Liu JW, Wei DZ and Yang SL: Refolding and purification of Apo2L/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. Biotechnol Lett 25: 2097-2101, 2003.
35. Lin Z, Lei H and Cao P: Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Protein Expr Purif 51: 276-282, 2007.
36. Wang D and Shi L: High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Appl Biochem Biotechnol 157: 1-9, 2009.
37. Saxena VP and Wetlaufer DB: Formation of three-dimensional structure in proteins. I. Rapid non-enzymic reactivation of reduced lysozyme. Biochemistry 25: 5015-5023, 1970.
38. Jaenicke R and Rudolph R: Folding proteins. In: Protein Structure, A Practical Approach. Creighton TE (ed.) IRL Press, Oxford, pp191-223, 1989.
39. Goto Y and Hamaguchi K: The role of the intrachain disulfide bond in the conformation and stability of the constant fragment of the immunoglobulin light chain. J Biochem 86: 1433-1441, 1979.